BioAtla Investor Presentation Deck

Encouraging Phase 1 results with Mecbotamab Vedotin (BA3011) in refractory NSCLC patients Maximum Change From Baseline (%) 100 80 60 40 20 0 -20 -40 -60 -80 -100 bicatla AXL- TmPS=0 1.5mg/kg d1,8 Response at Variable Dosing AXL- TmPS=0 1.2mg/kg d1,8 *1.8mg/kg d1,8 = 2Q3W dosing regimen Not Evaluable 1.2mg/kg d1 Confirmed PR Stage IV adenocarcinoma (multiple chemo PKIs and pembrolizumab failure) AXL+ TmPS-80 1.8mg/kg d1,8* A partial response was achieved in the AXL+ NSCLC patient refractory to multiple chemo PKIs and pembrolizumab failure BioAtla| Overview 17

View entire presentation